Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.
Advertisement

Related Content

Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)
Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
Pfizer's Crizotinib Eases Past FDA With Targeted Population
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process
CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies
Fast As A Whip, Pfizer Files Personalized Lung Cancer Drug Crizotinib

Topics

Advertisement
UsernamePublicRestriction

Register

PS072260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel